Biofrontera AG (ETR:B8FK)

Market Cap	14.71M -7.3%
Revenue (ttm)	13.19M -27.4%
Net Income	-3.97M
EPS	-0.65
Shares Out	6.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	164
Open	2.420
Previous Close	2.470
Day's Range	2.380 - 2.420
52-Week Range	2.160 - 2.960
Beta	-0.24
Analysts	n/a
Price Target	n/a
Earnings Date	May 31, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic produ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 74
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: B8FK

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -3.97 million, -8.85% less than in 2024.